Mitogard is being developed against certain brain injuries and nerve damage from chemical warfare agents.
Maas BiolAB and the Pilot Bioproduction Facility (PBF) of the Walter Reed Army Institute of Research (wrair-www.army.mil) (WRAIR) manufactured Mitogard®. WRAIR researchers note that the cyclosporin formulation was neuroprotective in models of traumatic brain injury and seizure-induced brain injury from organophosphate nerve agents.
WRAIR is researching the neuroprotective effects of cyclosporin against concussive and contusive traumatic brain injury and seizure-induced nerve damage from chemical warfare agents. WRAIR scientists Richard Bauman, Ph.D., and Joseph Long, Ph.D., have already shown improved outcomes with Maas cyclosporin formulae in animal models of brain injury from head trauma and nerve agents, according to a WRAIR spokesperson.
This production of Mitogard was funded by the Ft. Detrick Technology Transfer Initiative managed by the Maryland Technology Development. The program supports development of commercial technologies by the private sector to meet the needs of the U.S. Army Medical Research and Materiel Command.
The scale-up production of Mitogard is the first drug preparation by the PBF, which previously focused exclusively on vaccines.